Skip to main content

sildenafil

Generic: SILDENAFIL CITRATE·Brand: LIQREV, REVATIO, Revatio, SILDENAFIL CITRATE, VIAGRA, VYBRIQUE

sildenafil: developed by 2 companies · 1 clinical trial tracked · 3 FDA decisions.

sildenafil evidence translation

What we can confirm

3 FDA records · 1 tracked trial

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

What is verified about sildenafil, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Development Pipeline (2)
CompanyPhase
Teva Pharmaceutical Industries Limited (TEVA)Approved
Viatris Inc (VTRS)Approved
Clinical Trials (1)

Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men With Peyronie's Disease

NCT06649539·Phase 4·GHRS
Active, not recruiting

Primary endpoint: Penile Curvature

Interventionalopen40 targetStarted 2024-10Completion 2029-101 site · United StatesCharitable Union for the Research and Education of Peyronie's Disease
FDA Decisions3 records
Approval1 INDICATIONS AND USAGE Sildenafil tablets are indicated for the treatment of erectile dysfunction. Sildenafil tablets are a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) ( 1 )(TEVA)FDA ↗
ANDA077342OralTablet
Approval1 INDICATIONS AND USAGE Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14) ] . Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform (VTRS)FDA ↗
NDA203109Type 3 - New Dosage FormOrphan DrugPriorityOralFor Suspension
Approval1 INDICATIONS AND USAGE Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14) ] . Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform (VTRS)FDA ↗
NDA022473Type 3 - New Dosage FormStandardIntravenousSolution

Frequently asked questions

Who is developing sildenafil?

sildenafil is being developed by Teva Pharmaceutical Industries Limited, Viatris Inc.

How many clinical trials involve sildenafil?

BioSniper tracks 1 clinical trial involving sildenafil.

What is sildenafil's latest FDA decision?

The most recent tracked FDA decision for sildenafil is Approval for 1 INDICATIONS AND USAGE Sildenafil tablets are indicated for the treatment of erectile dysfunction. Sildenafil tablets are a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) ( 1 ), dated March 9, 2016.